CN111297949A - Essential oil mask and preparation method thereof - Google Patents
Essential oil mask and preparation method thereof Download PDFInfo
- Publication number
- CN111297949A CN111297949A CN202010196577.XA CN202010196577A CN111297949A CN 111297949 A CN111297949 A CN 111297949A CN 202010196577 A CN202010196577 A CN 202010196577A CN 111297949 A CN111297949 A CN 111297949A
- Authority
- CN
- China
- Prior art keywords
- oil
- portions
- mask
- essential
- bay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 106
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000003921 oil Substances 0.000 claims abstract description 125
- 235000019198 oils Nutrition 0.000 claims abstract description 125
- 239000010620 bay oil Substances 0.000 claims abstract description 59
- 239000001738 pogostemon cablin oil Substances 0.000 claims abstract description 45
- 239000011324 bead Substances 0.000 claims abstract description 19
- 241000212948 Cnidium Species 0.000 claims abstract description 14
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 14
- 239000010668 rosemary oil Substances 0.000 claims abstract description 14
- 229940058206 rosemary oil Drugs 0.000 claims abstract description 14
- 239000010677 tea tree oil Substances 0.000 claims abstract description 14
- 229940111630 tea tree oil Drugs 0.000 claims abstract description 14
- 241000131458 Elsholtzia Species 0.000 claims abstract description 11
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims abstract description 11
- 235000019477 peppermint oil Nutrition 0.000 claims abstract description 11
- 241001269712 Laggera Species 0.000 claims abstract description 10
- 239000010648 geranium oil Substances 0.000 claims abstract description 10
- 235000019717 geranium oil Nutrition 0.000 claims abstract description 10
- 241000218378 Magnolia Species 0.000 claims abstract description 8
- 241001252601 Blumea Species 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 66
- 239000000843 powder Substances 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 108010059892 Cellulase Proteins 0.000 claims description 15
- 244000147568 Laurus nobilis Species 0.000 claims description 15
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 15
- 240000002505 Pogostemon cablin Species 0.000 claims description 15
- 235000011751 Pogostemon cablin Nutrition 0.000 claims description 15
- 229940106157 cellulase Drugs 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 14
- 238000001256 steam distillation Methods 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 11
- 239000007790 solid phase Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 241001673966 Magnolia officinalis Species 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 5
- 125000005456 glyceride group Chemical group 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 5
- 239000001298 pelargonium graveolens oil Substances 0.000 claims description 4
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 3
- 240000006891 Artemisia vulgaris Species 0.000 claims description 3
- 241000013557 Plantaginaceae Species 0.000 claims description 3
- 241001072961 Pogostemon Species 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims description 2
- 241000533367 Cnidium officinale Species 0.000 claims 1
- 241000402754 Erythranthe moschata Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 20
- 241000700605 Viruses Species 0.000 abstract description 15
- 238000005422 blasting Methods 0.000 abstract description 11
- 230000003405 preventing effect Effects 0.000 abstract description 5
- 208000035473 Communicable disease Diseases 0.000 abstract description 4
- 230000000241 respiratory effect Effects 0.000 abstract description 4
- 238000001125 extrusion Methods 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 31
- 240000000278 Syzygium polyanthum Species 0.000 description 30
- 235000008089 Syzygium polyanthum Nutrition 0.000 description 30
- 241000712461 unidentified influenza virus Species 0.000 description 29
- 238000004821 distillation Methods 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 18
- 239000012071 phase Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 230000001717 pathogenic effect Effects 0.000 description 14
- 230000000840 anti-viral effect Effects 0.000 description 11
- 230000002195 synergetic effect Effects 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- 239000012154 double-distilled water Substances 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- 238000010298 pulverizing process Methods 0.000 description 7
- 238000007873 sieving Methods 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 239000011257 shell material Substances 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000255925 Diptera Species 0.000 description 3
- 206010069767 H1N1 influenza Diseases 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004880 explosion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 description 3
- 201000010740 swine influenza Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000366182 Melaleuca alternifolia Species 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 244000270673 Pelargonium graveolens Species 0.000 description 2
- 235000017927 Pelargonium graveolens Nutrition 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 description 2
- 240000001519 Verbena officinalis Species 0.000 description 2
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 description 2
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 description 2
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001846 repelling effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 2
- 229930004725 sesquiterpene Natural products 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 241001435059 Artemisia argyi Species 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000358234 Balanophora japonica Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 244000184421 Elsholtzia ciliata Species 0.000 description 1
- 235000006831 Elsholtzia ciliata Nutrition 0.000 description 1
- 241000132521 Erigeron Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 241001269715 Laggera pterodonta Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 241001479543 Mentha x piperita Species 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001309 inhibitory effect on influenza Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/10—Apiaceae or Umbelliferae [Carrot family], e.g. parsley, caraway, dill, lovage, fennel or snakebed
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/12—Asteraceae or Compositae [Aster or Sunflower family], e.g. daisy, pyrethrum, artichoke, lettuce, sunflower, wormwood or tarragon
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/22—Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/28—Myrtaceae [Myrtle family], e.g. teatree or clove
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1192—Protective face masks, e.g. for surgical use, or for use in foul atmospheres with antimicrobial agent
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D31/00—Materials specially adapted for outerwear
- A41D31/02—Layered materials
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D31/00—Materials specially adapted for outerwear
- A41D31/04—Materials specially adapted for outerwear characterised by special function or use
- A41D31/30—Antimicrobial, e.g. antibacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Virology (AREA)
- Textile Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of biomedicine, and particularly relates to an essential oil mask and a preparation method thereof. Essential oil gauze mask, including the gauze mask body, still including fixing at this internal pearl that explodes of gauze mask, explode the pearl and be used for breaking after the extrusion, explode the pearl and include the shell, the parcel has the essential oil in the shell, essential oil includes the following weight share's composition: 160 portions of tea tree oil, 140 portions of cnidium fruit oil, 120 portions of magnolia oil, 80 to 120 portions of patchouli oil, 140 portions of blumea oil, 180 portions of elsholtzia oil, 80 to 120 portions of rosemary oil, 160 portions of bay oil, 80 to 120 portions of geranium oil, 150 portions of peppermint oil and 150 portions of laggera oil. The essential oil mask has the function of inhibiting viruses by burying essential oil blasting beads. The technical scheme can be used for preventing respiratory diseases when respiratory infectious diseases are epidemic.
Description
Technical Field
The invention belongs to the technical field of biomedicine, and particularly relates to an essential oil mask and a preparation method thereof.
Background
The mask is a sanitary article worn at the mouth and nose part for filtering air entering the mouth and nose, can prevent harmful gas, smell and spray from entering and exiting the mouth and nose of a wearer, and is made of gauze, paper or non-woven fabrics and the like. The mask has a certain filtering function on air entering the lung, and has a very good protection function when the mask is worn for operation in an environment polluted by dust and the like when respiratory infectious diseases are prevalent. However, the mask in the prior art can only play a role of physically blocking pathogenic substances, and cannot actively kill pathogenic substances such as bacteria, viruses and the like. In the 21 st century, human beings suffer from various large-scale virus attacks, and influenza virus, SARS virus, MERS virus, novel coronavirus and the like continue to cause great harm to human society. The research and development of the mask with the effect of inhibiting or killing pathogenic substances are urgently needed, active defense and passive defense are managed together, and the protective effect of the mask on a wearer is improved.
Disclosure of Invention
The invention aims to provide an essential oil mask, which has the function of inhibiting viruses by burying essential oil blasting beads in a filling manner.
In order to solve the technical problems, the technical scheme of the invention is as follows:
the utility model provides an essential oil gauze mask, includes the gauze mask body, still including setting up at this internal pearl that explodes of gauze mask, it includes the shell that can break to explode the pearl, the parcel has essential oil in the shell, essential oil includes the composition of following parts by weight: 160 portions of tea tree oil, 140 portions of cnidium fruit oil, 120 portions of magnolia oil, 80 to 120 portions of patchouli oil, 140 portions of blumea oil, 180 portions of elsholtzia oil, 80 to 120 portions of rosemary oil, 160 portions of bay oil, 80 to 120 portions of geranium oil, 150 portions of peppermint oil and 150 portions of laggera oil.
By adopting the technical scheme, the technical principle is as follows: because the popping beads are fixed in the mask, when the mask is worn, the popping beads of the essential oil can be pinched off, the essential oil infiltrates the mask, the essential oil can play a role in inhibiting or killing pathogenic substances, and the mask can also play a role in physically blocking the external pathogenic substances. The essential oil content of the popsicle is as follows: tea tree oil is volatile oil (vegetable essential oil) extracted from Melaleuca alternifolia (Melaleuca alternifolia); cnidium fruit oil is volatile oil extracted from fruit of cnidium fruit (cnidiummonieri); magnolia bark oil is volatile oil extracted from root of Magnolia officinalis (Magnolia officinalis); patchouli oil is volatile oil extracted from whole plant of patchouli (Adenosmabuchneidenes); the oleum folium Artemisiae Argyi is volatile oil extracted from whole plant of folium Artemisiae Argyi (Artemisia argyi); elsholtzia oil is volatile oil extracted from the whole herb of Elsholtziaciliata; rosemary oil is volatile oil extracted from the whole herb of Rosmarinus officinalis (Rosmarinus officinalis), and laurel oil is volatile oil extracted from leaf of Laurus nobilis; pelargonium graveolens oil is volatile oil extracted from branches and leaves of Pelargonium graveolens (Pelargonium graveolens); peppermint oil is volatile oil extracted from the whole herb of peppermint (Mentha X piperita); laggera oil is volatile oil extracted from aerial parts of Laggera pterodonta. The inhibition effect on pathogenic substances is realized by the synergistic effect of various plant essential oils.
Wherein, the patchouli is the traditional spice plant for preventing and eliminating evil diseases, diminishing inflammation, sterilizing, repelling mosquitoes and preventing and treating cold in 400 years of the Hani nationality. Researchers have also performed both in vivo and clinical experiments in mice to verify the effect of patchouli oil in inhibiting influenza virus ("patchouli cold ointment experimental studies and field observations, chinese herbal medicine, 1987"), but the inhibitory effect of patchouli influenza virus needs to be achieved at higher doses. The inventor conducts a great deal of research on how to increase the virus inhibiting effect of the patchouli oil, and finds that the bay oil has synergistic effect on the anti-influenza virus effect of the patchouli oil although the bay oil has weak antiviral ability per se. The inventor further researches the action mechanism of the patchouli oil for inhibiting the influenza virus, and finds that the patchouli oil can inhibit the influenza virus in vitro, thereby inhibiting influenza virus infected cells, and further relieving the infection of the influenza virus to organisms, and the bay oil can enhance the in-vitro inhibition effect of the patchouli oil on the influenza virus. Due to the above mechanism, the patchouli oil is especially suitable for being applied to a mask, pathogenic substances such as viruses and the like can be blocked on the mask, and essential oil attached to the mask can simultaneously realize in-vitro inhibition on the pathogenic substances and reduce the infectivity and pathogenicity of the pathogenic substances.
Has the advantages that:
(1) when the multifunctional mask is used, the explosion beads are pinched and broken, the essential oil can infiltrate the mask, the essential oil attached to the mask volatilizes and can also play a role in inhibiting or killing pathogenic substances when the pathogenic substances are physically blocked by the mask, and the protection effect of the mask is improved. And when not wearing the gauze mask, explode the pearl and seal up the deposit with essential oil in inside, avoid essential oil to reveal and volatilize, guaranteed that essential oil can not volatilize or oxidation became invalid, and be convenient for transportation and storage.
(2) The essential oil in the populus is formed by compounding various plant extracts (mainly plant volatile oil), and integrates the effects of various volatile oils. The essential oil is used for removing pestilence, diminishing inflammation and sterilizing, removing evil and expelling dirt, refreshing and restoring consciousness, repelling mosquitoes and the like, and becomes an important traditional custom of people of all families in the world; in traditional Chinese medicine and pharmacology, the essential oil is considered to have the functions of clearing and activating the channels and collaterals, inducing resuscitation with aromatics and the like, has special fragrance and pharmacological activity, is a good material for aromatherapy, and meanwhile, on the mental level, the fragrance of the essential oil enables people to be delightful and has a certain conditioning effect.
(3) The laurel oil can promote inhibitory effect of oleum Rosae Laevigatae on influenza virus, and the combination of the two can effectively inhibit pathogenic substances and protect user health. The oleum Rosae Laevigatae can inhibit influenza virus in vitro, and the laurel oil can enhance the in vitro inhibitory effect of oleum Rosae Laevigatae on influenza virus.
(4) The essential oil mask is filled with the explosion beads containing essential oil, when the essential oil mask is used, the explosion beads containing the essential oil are pinched in the mask, and natural essential oil micromolecule compounds have the characteristics of strong volatility, activity and associativity, can be directly acted on an oral-nasal respiratory tract system, and avoid a short plate for orally taking medicines (the orally taken medicines can play the drug effect only through absorption, conversion, metabolism and other pharmacokinetic processes and through a long and complex action way). The essential oil mask has the characteristics of short action way and direct and quick generation of beneficial effects. In the way of virus infection, the essential oil mask can quickly play the roles of inhibiting virus and protecting human bodies (the essential oil micromolecule compound with extremely strong activity is easy to be compatible with virus macromolecules, so that the virus property is changed). The essential oil mask can be used for preventing human body from being infected with respiratory infectious diseases when the respiratory infectious diseases are epidemic.
Further, the magnolia oil is prepared by a carbon dioxide supercritical extraction method.
By adopting the technical scheme, the magnolia oil with high purity and good biological effect can be obtained.
Further, tea tree oil, cnidium fruit oil, patchouli oil, mugwort leaf oil, elsholtzia oil, rosemary oil, bay oil, geranium oil, peppermint oil and laggera oil are all prepared by steam distillation.
By adopting the technical scheme, the steam distillation method is a traditional essential oil extraction method, the operation is simple, and complex and expensive equipment is not needed.
Further, the patchouli oil is extracted from patchouli of Thymus of Scrophulariaceae.
By adopting the technical scheme, the essential oil extracted from the ophicalcitum (Adenosmabuchneidenes) (also called flea fleabane) of the plant of the genus Thymus of the family Scrophulariaceae mainly comprises terpenoids and phenolic compounds as effective chemical components. The oleum Rosae Laevigatae has antiviral effect and can kill pathogenic substances in upper respiratory tract. Clinical experiments show that the patchouli oil and the preparation thereof can prevent acute respiratory tract infection such as cold. If the patchouli oil is applied to the nasal and oral parts, the nasal obstruction can be relieved, and the ventilation is good; can prevent symptoms from aggravating after the application in the initial stage of the cold; it can also be applied to temple for treating dizziness and headache, and also has mosquito and insect bite preventing effect. Toxicological experiments show that the externally applied patchouli oil has no obvious side effect and skin allergy phenomenon.
Further, the bay oil is prepared by the following method: crushing fresh bay leaves to obtain bay leaf powder, carrying out cold leaching on the bay leaf powder by using ethyl acetate, and then filtering to obtain a solid phase to obtain a material A; performing enzymolysis treatment on the material A by using cellulase to obtain a material B; and (3) extracting the essential oil in the material B by using a steam distillation method to obtain the bay oil.
By adopting the technical scheme, the obtained bay oil has stronger promotion effect on the effect of the patchouli oil on inhibiting the influenza virus. The bay oil has a complex composition and is reported to contain 45 compounds including alkenes, alcohols, and the like. According to detection, the bay oil obtained after the ethyl acetate cold-soaking treatment has changed in component composition. The content of sesquiterpene oxide in the bay oil obtained by the technical scheme is reduced, the inventor analyzes that the sesquiterpene oxide has small synergistic effect on the patchouli oil, the substances are removed or partially removed due to the pretreatment of ethyl acetate, and the content of the component which has the effect of promoting the antiviral effect of the patchouli oil in the obtained bay oil is relatively increased. Therefore, the bay oil obtained by the technical scheme has stronger synergistic effect on the patchouli oil.
Furthermore, the dosage ratio of the laurel leaf powder to the ethyl acetate is 1g (5-9) ml, and the time for cold soaking the laurel leaf powder with the ethyl acetate is 1-2 h.
By adopting the technical scheme, the ethyl acetate treatment time is too short, and non-target functional components (components which cannot form a synergistic enhancement effect on the patchouli) cannot be effectively removed; and the long treatment time can cause the dissolution of the target functional components (the components which can form a synergistic effect on the patchouli oil). The time of the cold dipping treatment is a relatively critical factor.
Further, the material B is obtained by the following method: adding water and cellulase into the material A to obtain a system A; obtaining a system B after the system A is subjected to enzymolysis reaction; the material B is a solid phase in the system B.
By adopting the technical scheme, the cellulase breaks the cell wall structure, so that the intracellular components can be fully dissolved out, and the extraction efficiency is increased.
Further, the content of the cellulase in the system A is 1-2 wt%, the time of the enzymolysis reaction is 2-3h, the temperature of the enzymolysis reaction is 35-40 ℃, and the pH value of the enzymolysis reaction is 7.0-8.0.
By adopting the technical scheme, the enzymolysis reaction can be fully carried out.
Furthermore, the particle size of the blasting beads is 4.5-5.0 mm.
By adopting the technical scheme, the size is suitable for being loaded into a mask, and enough essential oil in the blasting beads is also ensured.
Further, the preparation method of the essential oil mask comprises the following steps:
(1) mixing tea tree oil, cnidium fruit oil, Magnolia officinalis oil, Pogostemon oil, folium Artemisiae Argyi oil, herba Moslae oil, Rosemary oil, laurel oil, Pelargonium graveolens oil, oleum Menthae Dementholatum and Lardizabalanopsis oil to obtain mixed oil;
(2) adding caprylic capric glyceride into the mixed oil, and diluting to obtain essential oil; or adding solubilizer and water into the mixed oil, and diluting to obtain the essential oil.
By adopting the technical scheme, the oil-soluble essential oil can be prepared by adding the caprylic capric glyceride into the mixed oil, and the water-soluble essential oil can be prepared by adding the solubilizer and the water into the mixed oil. Wherein, the water-soluble essential oil has higher bioavailability and better antiviral effect.
Drawings
Fig. 1 is a diagram of an example of the present invention 1.
Detailed Description
Example 1:
the utility model provides an essential oil gauze mask, includes the gauze mask body, and the gauze mask body is the gauze mask commonly used among the prior art, and the gauze mask body includes the oronasal occlusion part and is located the hangers portion of oronasal occlusion part both sides, and oronasal occlusion part stacks by double-deck thick gauze and forms, and double-deck thick gauze edge is sewed up. Each layer of thick gauze is formed by stacking a plurality of single-layer thin gauzes, the single-layer thin gauzes are sewn and fixed, and blasting beads are bonded between two adjacent layers of thick gauzes (the blasting beads are clamped between the double-layer thick gauzes). The number of the blasting beads can be determined according to actual needs, the blasting beads are spherical, and the particle size is 4.5-5.0 mm. The popball is formed by wrapping essential oil by a shell, the shell material (which is high molecular polymer and mainly comprises caprylic capric glyceride) of the popball is provided by Balanophora japonica biotechnology limited, and the popball is also produced by processing generation of the company (the inventor provides essential oil, and the company wraps the essential oil in the shell material), and the physical diagram of the popball is shown in figure 1. When the mask is used, essential oil in the popping beads can be released only by pinching and popping the popping beads, and the double-layer thick gauze is soaked. When a person wears the mask, the mask not only has the functions of filtering air and blocking external pathogenic substances, but also has the function of inhibiting viruses due to the essential oil on the mask.
The essential oil in the blasting beads comprises the following components in parts by weight: 140 parts of tea tree oil, 120 parts of cnidium fruit oil, 140 parts of mangnolia officinalis oil, 100 parts of patchouli oil, 120 parts of blumea oil, 140 parts of elsholtzia oil, 100 parts of rosemary oil, 130 parts of bay oil, 100 parts of geranium oil, 120 parts of peppermint oil and 130 parts of laggera oil. Tea tree oil, cnidium fruit oil, patchouli oil, blumea oil, elsholtzia oil, rosemary oil, bay oil, geranium oil, peppermint oil and laggera oil are all prepared by steam distillation, and magnolia oil is prepared by carbon dioxide supercritical extraction. The steam distillation method and the carbon dioxide supercritical extraction method are the existing mature plant essential oil extraction processes, and except for the patchouli oil and the laurel oil, other plant essential oils are purchased. The plant raw material is extracted by steam distillation or supercritical carbon dioxide extraction to obtain volatile oil, which is a conventional method in the prior art and will not be described repeatedly.
The preparation method of the patchouli oil comprises the following steps: pulverizing 50g fresh herba Cisii Japonici (whole plant), and sieving with 40 mesh sieve to obtain herba Cisii Japonici powder. Putting the patchouli powder into a round-bottomed flask, adding 300ml of cold water, installing a distillation device, heating and distilling (electrically heating, setting the temperature to be 110 ℃) until the first drop of liquid flows out of a condensation pipe, using a conical flask to hold and receive distillate for 3 hours, collecting the distillate after the distillation is finished, using a separating funnel to separate oil phase and water phase in the distillate, and using anhydrous sodium sulfate to treat the oil phase for 24 hours to obtain the patchouli oil. The preparation method of the bay oil comprises the following steps: pulverizing 50g fresh laurel leaf, and sieving with 40 mesh sieve to obtain laurel leaf powder. Adding 350ml ethyl acetate into laurel leaf powder, cold soaking for 2 hr, and filtering to obtain solid phase to obtain material A (laurel leaf powder soaked with ethyl acetate). And dispersing the material A in 50ml of pure water, and adding cellulase to obtain a system A, wherein the content of the cellulase in the system A is 2 wt%. Then, the enzymolysis reaction is carried out for 2.5h at the temperature of 37 ℃ and the pH value of 7.0. After the reaction is finished, obtaining a system B (containing the laurel leaf powder after enzymolysis, namely the material B), adding 300ml of pure water to obtain a distillation system, and carrying out steam distillation extraction on the distillation system. And (3) installing a distillation device, heating and distilling (electrically heating, setting the temperature to be 110 ℃) until the first drop of liquid flows out of the condensation pipe, using a conical flask to contain distillate, wherein the distillation time is 2 hours, collecting the distillate after the distillation is finished, using a separating funnel to separate an oil phase and a water phase in the distillate, and using anhydrous sodium sulfate to treat the oil phase for 24 hours to obtain the bay oil.
Mixing tea tree oil, cnidium fruit oil, Magnolia officinalis oil, oleum Rosae Laevigatae, folium Artemisiae Argyi oil, herba Moslae oil, Rosemary oil, laurel oil, Pelargonium graveolens oil, oleum Menthae Dementholatum and Lardizabalanus oil to obtain mixed oil, and adding water and solubilizer SF410 (Simplicol, Simplicin). The addition amount of the solubilizer SF410 is 2-4 times of the mixed oil, in the embodiment, the addition amount of the solubilizer SF410 is 4 times of the mixed oil, and the balance is pure water. The mixed oil is diluted to one tenth of the original mixed oil (in practice, the mixed oil can be diluted to one fifteenth to one eighth of the original mixed oil), and the essential oil (namely the water-soluble essential oil which contains 1 part of the mixed oil, 4 parts of the solubilizer SF410 and 5 parts of pure water) is obtained and is used for preparing the water-soluble blasting beads.
Example 2
This example is substantially the same as example 1, except that the preparation method of bay oil: pulverizing 50g fresh laurel leaf, and sieving with 40 mesh sieve to obtain laurel leaf powder. Adding 250ml ethyl acetate into laurel leaf powder, cold soaking for 2 hr, and filtering to obtain solid phase to obtain material A (laurel leaf powder soaked with ethyl acetate). And dispersing the material A in 50ml of pure water, and adding cellulase to obtain a system A, wherein the content of the cellulase in the system A is 1 wt%. Then carrying out enzymolysis reaction for 3h at 40 ℃ and pH value of 8.0. After the reaction is finished, obtaining a system B (containing the laurel leaf powder after enzymolysis), adding 300ml of pure water to obtain a distillation system, and carrying out steam distillation extraction on the distillation system. And (3) installing a distillation device, heating and distilling (electrically heating, setting the temperature to be 110 ℃) until the first drop of liquid flows out of the condensation pipe, using a conical flask to contain distillate, wherein the distillation time is 2 hours, collecting the distillate after the distillation is finished, using a separating funnel to separate an oil phase and a water phase in the distillate, and using anhydrous sodium sulfate to treat the oil phase for 24 hours to obtain the bay oil.
The difference is also that the formula of the essential oil is as follows: 160 parts of tea tree oil, 140 parts of cnidium fruit oil, 160 parts of mangnolia officinalis oil, 120 parts of verbena oil, 140 parts of blumea oil, 180 parts of elsholtzia oil, 120 parts of rosemary oil, 160 parts of bay oil, 120 parts of geranium oil, 150 parts of peppermint oil and 150 parts of laggera oil.
This example prepared an oily essential oil, which was a mixture of tea tree oil, cnidium seed oil, magnolia oil, patchouli oil, mugwort leaf oil, elsholtzia oil, rosemary oil, bay oil, geranium oil, peppermint oil, and pteridan oil. And adding food-grade caprylic capric glyceride (MCT) into the mixed oil, diluting the mixed oil to one tenth of the original mixed oil (in actual operation, the mixed oil can be diluted to one fifteenth to one eighth of the original mixed oil), and obtaining essential oil (oil-soluble essential oil, wherein the essential oil contains 1 part of mixed oil and 9 parts of MCT), and the essential oil is used for preparing oily popcorns.
Example 3
This example is substantially the same as example 1, except that the preparation method of bay oil: pulverizing 50g fresh laurel leaf, and sieving with 40 mesh sieve to obtain laurel leaf powder. Adding 450ml ethyl acetate into laurel leaf powder, cold soaking for 1h, and filtering to obtain solid phase to obtain material A (laurel leaf powder soaked with ethyl acetate). And dispersing the material A in 50ml of pure water, and adding cellulase to obtain a system A, wherein the content of the cellulase in the system A is 2 wt%. Then carrying out enzymolysis reaction for 2h at 35 ℃ and pH value of 7.0. After the reaction is finished, obtaining a system B (containing the laurel leaf powder after enzymolysis), adding 300ml of pure water to obtain a distillation system, and carrying out steam distillation extraction on the distillation system. And (3) installing a distillation device, heating and distilling (electrically heating, setting the temperature to be 110 ℃) until the first drop of liquid flows out of the condensation pipe, using a conical flask to contain distillate, wherein the distillation time is 2 hours, collecting the distillate after the distillation is finished, using a separating funnel to separate an oil phase and a water phase in the distillate, and using anhydrous sodium sulfate to treat the oil phase for 24 hours to obtain the bay oil.
The difference is also that the formula of the essential oil is as follows: 120 parts of tea tree oil, 100 parts of cnidium fruit oil, 120 parts of mangnolia officinalis oil, 80 parts of verbena oil, 100 parts of blumea oil, 120 parts of elsholtzia oil, 80 parts of rosemary oil, 100 parts of bay oil, 80 parts of geranium oil, 100 parts of peppermint oil and 100 parts of laggera oil.
Comparative example 1
This comparative example is substantially the same as example 1, except that the preparation process of bay oil (direct distillation, no distillation pretreatment step): pulverizing 50g fresh laurel leaf, and sieving with 40 mesh sieve to obtain laurel leaf powder. Laurel leaf powder was charged into a round-bottomed flask, and 300ml of pure water was added to obtain a distillation system, which was subjected to steam distillation extraction. And (3) installing a distillation device, heating and distilling (electrically heating, setting the temperature to be 110 ℃) until the first drop of liquid flows out of the condensation pipe, using a conical flask to contain distillate, wherein the distillation time is 2 hours, collecting the distillate after the distillation is finished, using a separating funnel to separate an oil phase and a water phase in the distillate, and using anhydrous sodium sulfate to treat the oil phase for 24 hours to obtain the bay oil.
Comparative example 2
This comparative example is substantially the same as example 1, except that the bay oil was prepared by the method comprising: pulverizing 50g fresh laurel leaf, and sieving with 40 mesh sieve to obtain laurel leaf powder. Adding 350ml ethyl acetate into laurel leaf powder, cold soaking for 2 hr, and filtering to obtain solid phase to obtain material A (laurel leaf powder soaked with ethyl acetate). Directly adding 300ml of pure water into the material A without an enzymolysis step, and obtaining the bay oil after steam distillation.
Comparative example 3
This comparative example is substantially the same as example 1, except that the bay oil was prepared by the method comprising: pulverizing 50g fresh laurel leaf, and sieving with 40 mesh sieve to obtain laurel leaf powder. Adding 50ml of pure water into bay leaf powder, and adding cellulase to obtain a system A, wherein the content of the cellulase in the system A is 2 wt%. Then, the enzymolysis reaction is carried out for 2.5h at the temperature of 37 ℃ and the pH value of 7.0. After the reaction is finished, obtaining a system B (containing the laurel leaf powder after enzymolysis). Further adding 300ml of pure water to obtain a distillation system, and performing steam distillation extraction on the distillation system to obtain the bay oil.
Comparative example 4
This comparative example is essentially the same as example 1 except that bay oil is not added to the essential oil.
Comparative example 5
This comparative example is substantially the same as example 1 except that the lauryl leaf powder was cold-dipped with ethyl acetate for 5 hours.
Experimental example: viral inhibitory Effect
This example investigated the inhibitory effect of the test agent on the ability of the virus to infect after it has acted extracellularly with the virus. Experimental grouping was as follows:
(1) negative control group: the test reagent is sterilized double distilled water;
(2) positive control group: the test reagent is ribavirin injection (Chinese medicine standard H41023268), and the ribavirin injection is diluted by one tenth of sterilized double distilled water in a sterile environment to obtain the test reagent;
(3) experimental group 1: the test reagent is the essential oil (water-soluble essential oil) of example 1, and the essential oil needs to be subjected to filtration sterilization treatment and then to subsequent cell experiments;
(4) experimental group 2: the test reagent is the essential oil (water-soluble essential oil) prepared in the comparative example 4, and the essential oil needs to be subjected to filtration sterilization treatment and then to subsequent cell experiments;
(5) experimental group 3: the test reagent is the patchouli oil prepared in the example 1, 0.84ml of water and 400 μ l of SF410 are added into 100 μ l of patchouli oil, after uniform mixing, the patchouli oil is diluted by one tenth of sterilized double distilled water to obtain the test reagent, and the test reagent needs to be filtered and sterilized firstly and then is subjected to subsequent cell experiments;
(6) experimental group 4: the test reagents are the patchouli oil and the bay oil prepared in the example 1, the patchouli oil and the bay oil are mixed according to the ratio of 1:1.3 to obtain mixed oil, then 0.19ml of water and 920 μ l of SF410 are added into 230 μ l of the mixed oil, after the mixed oil is mixed uniformly, the mixed oil is diluted by one tenth of sterilized double distilled water to obtain the test reagent, the test reagent needs to be filtered and sterilized firstly, and then the subsequent cell experiment is carried out;
(7) experimental group 5: the test reagents were patchouli oil and bay oil prepared in comparative example 1, and were prepared as in (6);
(8) experimental group 6: the test reagents were patchouli oil and bay oil prepared in comparative example 2, prepared as in (6);
(9) experimental group 7: the test reagents were patchouli oil and bay oil prepared in comparative example 3, prepared as in (6);
(10) experimental group 8: the test reagents were patchouli oil and bay oil prepared in comparative example 5, prepared as in (6);
(11) experimental group 9: the test reagent is the bay oil prepared in example 1, 0.69ml of water and 520 ul of SF410 are added into 130 ul of bay oil, after uniform mixing, the bay oil is diluted by one tenth of sterilized double distilled water to obtain the test reagent, and the test reagent needs to be filtered and sterilized;
(12) blank control group: the test reagent is sterilized double distilled water which is not incubated with H1N1 influenza virus diluent, and 20 mul of sterilized double distilled water is directly added into MDCK single-layer cells.
The cell used in this experimental example was a dog kidney passaged cell (MDCK), and the virus strain used was the H1N1 influenza virus strain. Firstly, a test reagent is mixed with H1N1 influenza virus diluent (with the titer of 2)4HAU) was mixed (volume ratio 1: 1) to obtain a mixed solution, and incubated at 37 ℃ for 2 hours. Then 20. mu.l of the mixture was added to MDCK monolayer cells (MDCK cell inoculation as 1X 104One well was inoculated in a 96-well plate, and a MEM medium containing 5% bovine serum was added to culture until MDCK monolayer cells were formed), and after 1 hour of infection, 100. mu.l of a MEM medium containing 5% bovine serum was added and placed in an incubator to culture for 24 hours. After the experiment is finished, the survival rate of the MDCK cells is detected by a CCK-8 method. Discarding the culture medium from the cells in the 96-well plate, adding CCK-8 solution (using the culture medium to dilute CCK-8 stock solution to be one percent of the stock solution), incubating for 2h, and using an enzyme-labeling instrument at 5 DEGThe OD value of each well was measured at 70nm, and the cell viability was calculated from the OD value.
Table 1: results of Virus inhibition experiments (3 replicates per experimental group)
The results are shown in table 1 and analyzed as follows:
the data of the negative control group show that the influenza virus used in the experiment can effectively infect MDCK cells, resulting in the reduction of the survival rate of the MDCK cells. The data of the positive control show that the commonly used drug ribavirin can effectively inhibit influenza virus and reduce the killing effect of the influenza virus on MDCK cells, and the ribavirin with the concentration does not show obvious cytotoxicity. The cells of the blank control group are not invaded by influenza virus, the cell activity is high, the survival rate is high, and the cells used in the experiment are proved to have higher activity. In the blank control group, the survival rate of MDCK cells was greatly affected by the invasion of influenza virus compared with the negative control group.
The test group 4 used the patchouli oil and bay oil prepared in example 1, and the test agent of test group 4 had a stronger inhibitory effect on influenza virus than those of test groups 9 and 3, so that the killing effect of influenza virus on MDCK cells was reduced. From the data of experimental group 3, it is clear that the patchouli oil alone has a certain effect on the inhibition of influenza virus, but its effect is not very prominent compared to the positive control ribavirin. As can be seen from experiment group 9, the effect of inhibiting influenza virus by using laurel oil alone is very weak and is basically equal to the effect of double distilled water (see negative control), but experiment group 4 adds laurel oil into the patchouli oil, and the laurel oil can enhance the effect of inhibiting influenza virus by the patchouli oil.
Experimental group 5 used the patchouli oil and the bay oil prepared in comparative example 1, and since the bay oil of this group was obtained by directly distilling and extracting bay leaf powder, the bay oil had a less potent antiviral effect on patchouli than the bay oil prepared in example 1. In the experimental group 6, the laurel leaf powder cold-soaked with ethyl acetate was not subjected to the enzymatic treatment, but the obtained laurel oil was not much different in the efficacy of promoting the antiviral ability of patchouli, compared with the laurel oil of example 1. However, the yield of the bay oil is significantly reduced during the extraction process. In the experimental group 7, the effect of the bay oil on promoting the antiviral ability of the patchouli is reduced compared with the bay oil of the example 1. Comparative example 3 the bay leaf powder was not soaked with ethyl acetate, resulting in the bay oil finally obtained containing more impurities (referring to the components not having the efficacy of promoting the antiviral ability of patchouli). In the finally obtained laurel oil, the content of effective components (components with effect of promoting antiviral ability of herba Cisii) is reduced, resulting in weakening effect of laurel oil. Experimental group 8 using the bay oil prepared in comparative example 5, the bay leaf powder was treated with ethyl acetate for a long time, resulting in loss of part of the functional ingredients (i.e., ingredients having the effect of promoting the antiviral ability of patchouli), and the content of the functional ingredients was reduced in the finally obtained bay oil. The ethyl acetate cold-soaking treatment of the laurel leaf powder for a certain time can enable partial substances in the laurel leaf powder to be leached out, and the partial substances do not have synergistic effect on the patchouli oil. However, the long time of the cold soaking treatment can cause a great amount of substances in the bay leaf powder to be dissolved out, and the substances also comprise functional components with synergistic enhancement effect on the patchouli, so the time of the cold soaking treatment is a relatively critical factor, and the proper time of the cold soaking treatment can ensure that the bay oil contains a relatively large amount of target functional components (components capable of forming synergistic enhancement effect on the patchouli oil) and can also reduce the existence of impurities (components incapable of forming synergistic enhancement effect on the patchouli) as much as possible.
The experiment group 1 uses the full-component essential oil in the blasting beads, and all components have synergistic effect, so that the influenza virus inhibitor has a good influenza virus inhibition effect. In the experimental group 2, the bay oil is absent from the essential oil, and the effect of the essential oil on inhibiting influenza viruses is weakened, which shows that although the bay oil has weak antiviral effect, the bay oil has the effect of promoting the essential oil formula to resist the influenza viruses.
The foregoing is merely an example of the present invention and common general knowledge of known specific structures and features of the embodiments is not described herein in any greater detail. It should be noted that, for those skilled in the art, without departing from the structure of the present invention, several changes and modifications can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicability of the patent. The scope of the claims of the present application shall be determined by the contents of the claims, and the description of the embodiments and the like in the specification shall be used to explain the contents of the claims.
Claims (10)
1. The utility model provides an essential oil gauze mask, includes the gauze mask body, its characterized in that still including setting up at this internal pearl that explodes of gauze mask, it includes the shell that can break to explode the pearl, the parcel has essential oil in the shell, essential oil includes the composition of following part by weight: 160 portions of tea tree oil, 140 portions of cnidium fruit oil, 120 portions of magnolia oil, 80 to 120 portions of patchouli oil, 140 portions of blumea oil, 180 portions of elsholtzia oil, 80 to 120 portions of rosemary oil, 160 portions of bay oil, 80 to 120 portions of geranium oil, 150 portions of peppermint oil and 150 portions of laggera oil.
2. The essential oil mask of claim 1, wherein the magnolia oil is prepared by supercritical carbon dioxide extraction.
3. The mask containing essential oils of claim 2, wherein the tea tree oil, cnidium officinale oil, patchouli oil, mugwort leaf oil, elsholtzia oil, rosemary oil, bay oil, geranium oil, peppermint oil and laggera oil are prepared by steam distillation.
4. An essential oil mask as claimed in claim 3, wherein the patchouli oil is extracted from patchouli of the genus Musk of the family Scrophulariaceae.
5. The essential oil mask of claim 4 wherein the lauric oil is prepared by the following method: crushing fresh bay leaves to obtain bay leaf powder, carrying out cold leaching on the bay leaf powder by using ethyl acetate, and then filtering to obtain a solid phase to obtain a material A; performing enzymolysis treatment on the material A by using cellulase to obtain a material B; and (3) extracting the essential oil in the material B by using a steam distillation method to obtain the bay oil.
6. The mask containing essential oils of claim 5, wherein the ratio of the bay leaf powder to the ethyl acetate is 1g (5-9) ml, and the bay leaf powder is treated by cold soaking with ethyl acetate for 1-2 h.
7. The essential oil mask as claimed in claim 6, wherein the material B is obtained by the following method: adding water and cellulase into the material A to obtain a system A; obtaining a system B after the system A is subjected to enzymolysis reaction; the material B is a solid phase in the system B.
8. The essential oil mask as claimed in claim 7, wherein the content of cellulase in the system A is 1-2 wt%, the time of enzymolysis reaction is 2-3h, the temperature of enzymolysis reaction is 35-40 ℃, and the pH value of enzymolysis reaction is 7.0-8.0.
9. The oil mask according to any one of claims 1 to 8, wherein the size of the exploded bead is 4.5 to 5.0 mm.
10. The method for manufacturing an essential oil mask according to claim 9, comprising the steps of:
(1) mixing tea tree oil, cnidium fruit oil, Magnolia officinalis oil, Pogostemon oil, folium Artemisiae Argyi oil, herba Moslae oil, Rosemary oil, laurel oil, Pelargonium graveolens oil, oleum Menthae Dementholatum and Lardizabalanopsis oil to obtain mixed oil;
(2) adding caprylic capric glyceride into the mixed oil, and diluting to obtain essential oil; or adding solubilizer and water into the mixed oil, and diluting to obtain the essential oil.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010196577.XA CN111297949A (en) | 2020-03-19 | 2020-03-19 | Essential oil mask and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010196577.XA CN111297949A (en) | 2020-03-19 | 2020-03-19 | Essential oil mask and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111297949A true CN111297949A (en) | 2020-06-19 |
Family
ID=71151450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010196577.XA Pending CN111297949A (en) | 2020-03-19 | 2020-03-19 | Essential oil mask and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111297949A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113332400A (en) * | 2021-05-18 | 2021-09-03 | 江西中医药大学 | Antiviral traditional Chinese medicine volatile oil composition and application thereof |
CN114246925A (en) * | 2020-09-22 | 2022-03-29 | 香港科技大学 | Traditional Chinese medicine essential oil and application thereof |
JP2022084323A (en) * | 2020-11-26 | 2022-06-07 | 株式会社山正 | Mugwort extraction composition having antiviral action, and mask or filter including the same |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1703959A (en) * | 2004-05-31 | 2005-12-07 | 汕头市双骏生物工程有限公司 | Preparation capable of killing virus and bacteria and its preparation process |
CN101306080A (en) * | 2007-05-17 | 2008-11-19 | 厦门金日制药有限公司 | Elsholtzia spray |
DE202009007670U1 (en) * | 2009-05-29 | 2009-08-13 | Jentsch, Peter | A composition for coating a surface with a microorganism repellent layer |
CN106342946A (en) * | 2016-08-02 | 2017-01-25 | 中山圣菲环保科技有限公司 | Air purification disinfectant and method for preparing same |
CN107468758A (en) * | 2016-09-08 | 2017-12-15 | 安徽香杰香精科技有限公司 | One kind is refreshed oneself anti-flu compound essential oil and its application method |
CN207492133U (en) * | 2017-05-17 | 2018-06-15 | 联合诺华(天津)有限公司 | A kind of removably essential oil mask |
CN109042748A (en) * | 2018-11-06 | 2018-12-21 | 上海澳克林新材料科技有限公司 | A kind of sterilizing and anti-virus plants essential oil and preparation method thereof |
CN109662984A (en) * | 2019-02-13 | 2019-04-23 | 昆明医科大学 | The application of laggera pterodonta and Rosmarinus officinalis extract in anti-II type dengue virus drug |
CN109700771A (en) * | 2019-01-31 | 2019-05-03 | 安徽仙奇生物工程技术有限公司 | Alleviate quick-fried pearl, preparation method and the amenities containing quick-fried pearl of nasal obstruction |
CN110859872A (en) * | 2019-12-04 | 2020-03-06 | 湖北创界生物科技有限公司 | Anti-inflammatory and bactericidal essential oil composition, and preparation method and application thereof |
-
2020
- 2020-03-19 CN CN202010196577.XA patent/CN111297949A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1703959A (en) * | 2004-05-31 | 2005-12-07 | 汕头市双骏生物工程有限公司 | Preparation capable of killing virus and bacteria and its preparation process |
CN101306080A (en) * | 2007-05-17 | 2008-11-19 | 厦门金日制药有限公司 | Elsholtzia spray |
DE202009007670U1 (en) * | 2009-05-29 | 2009-08-13 | Jentsch, Peter | A composition for coating a surface with a microorganism repellent layer |
CN106342946A (en) * | 2016-08-02 | 2017-01-25 | 中山圣菲环保科技有限公司 | Air purification disinfectant and method for preparing same |
CN107468758A (en) * | 2016-09-08 | 2017-12-15 | 安徽香杰香精科技有限公司 | One kind is refreshed oneself anti-flu compound essential oil and its application method |
CN207492133U (en) * | 2017-05-17 | 2018-06-15 | 联合诺华(天津)有限公司 | A kind of removably essential oil mask |
CN109042748A (en) * | 2018-11-06 | 2018-12-21 | 上海澳克林新材料科技有限公司 | A kind of sterilizing and anti-virus plants essential oil and preparation method thereof |
CN109700771A (en) * | 2019-01-31 | 2019-05-03 | 安徽仙奇生物工程技术有限公司 | Alleviate quick-fried pearl, preparation method and the amenities containing quick-fried pearl of nasal obstruction |
CN109662984A (en) * | 2019-02-13 | 2019-04-23 | 昆明医科大学 | The application of laggera pterodonta and Rosmarinus officinalis extract in anti-II type dengue virus drug |
CN110859872A (en) * | 2019-12-04 | 2020-03-06 | 湖北创界生物科技有限公司 | Anti-inflammatory and bactericidal essential oil composition, and preparation method and application thereof |
Non-Patent Citations (4)
Title |
---|
吴建挺等: "11种植物精油对6种植物病原真菌的抑菌活性研究", 《植物科学学报》 * |
尹莲: "《天然药物化学》", 31 July 2017, 中国中医药出版社 * |
徐少春 等: "刺蕊草防感冒油膏实验研究与现场观察", 《中草药》 * |
王克林 等: "《中医药治疗流感的研究与临床》", 31 March 2011, 中国中医药出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114246925A (en) * | 2020-09-22 | 2022-03-29 | 香港科技大学 | Traditional Chinese medicine essential oil and application thereof |
JP2022084323A (en) * | 2020-11-26 | 2022-06-07 | 株式会社山正 | Mugwort extraction composition having antiviral action, and mask or filter including the same |
JP7162818B2 (en) | 2020-11-26 | 2022-10-31 | 株式会社山正 | Mugwort extract composition having antiviral activity, and mask or filter using the same |
CN113332400A (en) * | 2021-05-18 | 2021-09-03 | 江西中医药大学 | Antiviral traditional Chinese medicine volatile oil composition and application thereof |
CN113332400B (en) * | 2021-05-18 | 2022-12-13 | 江西中医药大学 | Antiviral traditional Chinese medicine volatile oil composition and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111297949A (en) | Essential oil mask and preparation method thereof | |
CN106538638A (en) | A kind of Chinese medicine antiseptic and preparation method thereof | |
CN101946990A (en) | Nano silver selenium negative ion anti-bacterial face mask for controlling H1N1 influenza | |
CN102085311B (en) | Traditional Chinese medicinal composition for preventing or treating common cold and/or flu, method for preparing same and application thereof | |
CN103504901A (en) | Traditional Chinese medicine health care pillow | |
CN100444734C (en) | A compound antivirus sprayer and preparation method thereof | |
CN101953763A (en) | Chinese medicinal herb repellent liquid | |
CN114246925A (en) | Traditional Chinese medicine essential oil and application thereof | |
CN114916564A (en) | Essential oil composition for inhibiting novel coronavirus | |
Kovendan et al. | Green synthesis of Malvastrum coromandelianum fabricated AgNPs: Anti-dengue and mosquitocidal studies | |
KR20220156604A (en) | Application of Traditional Chinese Medicine Compositions in Preparation of Drugs for Treatment or Prevention of Coronavirus Infection | |
Petrera | Antiviral and immunomodulatory properties of Meliaceae family | |
CN105711513A (en) | Natural mosquito-repellent plant and active mineral combined front-wall sound-insulating pad for automobile | |
TW201442719A (en) | Use of Anisomeles indica (L.) Kuntze extract and purified products thereof against influenza virus | |
US8518435B2 (en) | Homeopathic formulation consisting of Bryonia alba and Pulsatilla spp | |
CN106692504A (en) | Anti-haze health food capable of clearing heat from throat, relieving cough and moistening lung and preparation method thereof | |
Mustafa et al. | Investigation of antiviral effects of essential oils | |
CN103815587A (en) | Mask capable of preventing inhalation of harmful tiny particulate matters in air effectively and inhibiting bacteria and production method of mask | |
US20080102140A1 (en) | Use of solidago virgaurea in the treatment and prevention of viral infections | |
Hemalika et al. | Anti-dengue effects of medicinal plants: A review | |
CN111450297A (en) | Marine fucoidin herbal atomizing agent and preparation method thereof | |
CN114903932B (en) | Improved Jinyanjian medicinal composition, microemulsion aerosol inhalant, preparation method and application | |
CN111514246A (en) | Traditional Chinese medicine composition and mask for preventing novel coronavirus pneumonia | |
CN111419905A (en) | Traditional Chinese medicine insect expelling composition and preparation method thereof | |
CN110742924A (en) | Traditional Chinese medicine volatile oil composition and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200619 |
|
RJ01 | Rejection of invention patent application after publication |